Dimensional Fund Advisors LP Raises Holdings in MaxCyte, Inc. (NASDAQ:MXCT)

Dimensional Fund Advisors LP raised its position in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 15.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,429,071 shares of the company's stock after acquiring an additional 191,088 shares during the period. Dimensional Fund Advisors LP owned approximately 1.35% of MaxCyte worth $5,945,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. Prudential Financial Inc. bought a new stake in MaxCyte in the fourth quarter worth about $65,000. Catalyst Funds Management Pty Ltd bought a new position in shares of MaxCyte during the fourth quarter valued at approximately $74,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of MaxCyte by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company's stock worth $93,000 after buying an additional 2,154 shares during the period. EntryPoint Capital LLC bought a new stake in shares of MaxCyte during the 4th quarter worth approximately $185,000. Finally, SG Americas Securities LLC lifted its stake in shares of MaxCyte by 25.9% during the 4th quarter. SG Americas Securities LLC now owns 47,805 shares of the company's stock worth $199,000 after acquiring an additional 9,836 shares during the last quarter. Institutional investors own 68.81% of the company's stock.

MaxCyte Stock Performance

Shares of MaxCyte stock remained flat at $2.20 on Wednesday. 1,325,247 shares of the stock traded hands, compared to its average volume of 548,102. The stock has a market cap of $233.90 million, a P/E ratio of -6.47 and a beta of 1.38. The company has a 50 day moving average of $2.78 and a 200 day moving average of $3.60. MaxCyte, Inc. has a 1 year low of $2.15 and a 1 year high of $5.26.

MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The business had revenue of $10.39 million during the quarter, compared to analysts' expectations of $9.05 million. On average, analysts forecast that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MXCT has been the topic of a number of recent analyst reports. Stifel Nicolaus reduced their target price on MaxCyte from $11.00 to $9.00 and set a "buy" rating on the stock in a research note on Wednesday, March 12th. BTIG Research set a $6.00 price target on shares of MaxCyte and gave the stock a "buy" rating in a research note on Wednesday, March 12th.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.